← Leaderboards
Miguel Garcia-Guzman
Aspyrian Therapeutics, Inc.
$758,483
Attributed
$966,765
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $834.1K · FY2011–13$1M$750K$500K$250K$0
'11
'12
'13
Funding mix
By agency
NIH$966,765 · 3
By mechanism
R43$834,104 · 2
R41$132,661 · 1
Top collaborators
- Deborah Slee1 shared
Most similar at Aspyrian Therapeutics, Inc.
Same institution · by research overlap
- Deborah Slee$663,221
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoBasePre-ClinicalPropertyDoseEvaluationFuturePharmaceutical PreparationsValidationSafetyAllodyniaAnti-Inflammatory AgentsAntineoplastic AgentsApplications GrantsAnti-InflammatoryAgonistAcute PainAntiepileptic AgentsCancer TherapyBiopsyCaringCell LineCellsAntidepressive Agents